Comparative Pharmacology
Head-to-head clinical analysis: PHOSPHOTOPE versus TECHNETIUM TC 99M MEDRONATE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHOSPHOTOPE versus TECHNETIUM TC 99M MEDRONATE KIT.
PHOSPHOTOPE vs TECHNETIUM TC-99M MEDRONATE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; proposed to normalize phosphate metabolism and inhibit ectopic calcification by binding to calcium and phosphate.
Technetium Tc-99m medronate (MDP) is a bone-seeking radiopharmaceutical that binds to calcium ions in hydroxyapatite crystals of bone. Uptake is proportional to osteoblastic activity and regional blood flow, allowing scintigraphic imaging of skeletal structures.
10-20 mcg/kg intravenous bolus over 1-2 minutes, may repeat every 10-20 minutes as needed for hemodynamic support. Maximum total dose: 1 mg.
Intravenous injection: 370-1110 MBq (10-30 mCi) for bone imaging. Adult dose is administered once for each imaging procedure.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in patients with normal renal function; prolonged to 12-24 hours in moderate renal impairment (CrCl <30 mL/min) and >24 hours in dialysis-dependent patients.
Terminal elimination half-life: 6.02 hours (range 5.8–6.3 hours) in patients with normal renal function; prolonged in renal impairment.
Renal: 70-80% as unchanged drug; fecal: 15-20% as metabolites; biliary: <5%.
Renal: approximately 50% of injected dose excreted unchanged in urine within 24 hours. Biliary/fecal: less than 5%.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical